AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
12.4 C
New York
Tuesday, October 20, 2026

Tag: cardiovascular

Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED

– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect –

Cardiawave Announces First Routine Treatments Performed with Valvosoft® Following CE Mark Approval and Accelerates Its Deployment

Cardiawave Announces First Routine Treatments Performed with Valvosoft® Following CE Mark Approval and Accelerates Its Deployment

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

MELBOURNE, Australia, June 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications, notably a composition-of-matter patent and method-of-use for its Toll-like receptor 2 (TLR2) therapies.

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

HorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?

Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

ZELUS LAUNCHES HOME TACTICAL FITNESS INITIATIVE FOR OFF-DUTY LAW ENFORCEMENT, DEPLOYING MISSION-GRADE DESIGN TO HOME GYMS

LAKE FOREST, Calif., June 12, 2026 /PRNewswire/ -- Zelus, a global leader in innovative athletic equipment and an Amazon bestseller in wearable resistance, has officially...

ZELUS LAUNCHES HOME TACTICAL FITNESS INITIATIVE FOR OFF-DUTY LAW ENFORCEMENT, DEPLOYING MISSION-GRADE DESIGN TO HOME GYMS

LAKE FOREST, Calif., June 12, 2026 /PRNewswire/ -- Zelus, a global leader in innovative athletic equipment and an Amazon bestseller in wearable resistance, has officially...

KFSH Highlights the Strategic Value of Tertiary Care AI Datasets in Advancing Precision Medicine and Clinical Innovation

RIYADH, Saudi Arabia, June 12, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will use its participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, to highlight the strategic value of tertiary care datasets as a foundation for advancing artificial intelligence, precision medicine, and clinical innovation in highly specialized healthcare.

UK’s leading longevity clinic Get A Drip appoints new Chief Medical Officer Dr Luke Pratsides

LONDON, June 12, 2026 /PRNewswire/ -- Get A Drip, one of the UK's largest providers of longevity health treatments, is strengthening its clinical leadership...

The Galien Foundation Honours Leaders in Life Sciences Innovation with the 2026 Prix Galien UK Awards

-- Winners across biotechnology, digital health, medical technology, pharmaceuticals, public sector, and health equity categories honoured at prestigious Awards Ceremony LONDON, June 12, 2026...

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCardiovascular